120 related articles for article (PubMed ID: 25039087)
21. Active surveillance: oncologic outcome.
Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
23. Editorial comment.
Carroll PR; Whitson JM
Urology; 2011 Apr; 77(4):984-5. PubMed ID: 21477729
[No Abstract] [Full Text] [Related]
24. Active surveillance preferred for low-risk prostate cancer.
Bagcchi S
Lancet Oncol; 2015 Aug; 16(8):e384. PubMed ID: 26190749
[No Abstract] [Full Text] [Related]
25. [Optimization of follow up in prostate cancer active surveillance].
Celma Domènech A; Planas Morin J; Morote Robles J
Arch Esp Urol; 2014 Jun; 67(5):442-51. PubMed ID: 24914843
[TBL] [Abstract][Full Text] [Related]
26. [Results of active surveillance in low and intermediate risk prostate cancer].
Llorente C; Diaz Goizueta FJ; Hernandez V; de la Morena JM; de la Peña E
Arch Esp Urol; 2014 Jun; 67(5):452-6. PubMed ID: 24914844
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer diagnosis: surgery or not?
Aust Nurs J; 2012 Nov; 20(5):49. PubMed ID: 23316506
[No Abstract] [Full Text] [Related]
28. [Active surveillance of prostatic cancer].
Vasarainen H; Ruutu M; Rannikko A
Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523
[TBL] [Abstract][Full Text] [Related]
29. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ
Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549
[TBL] [Abstract][Full Text] [Related]
30. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
Bailey DE; Wallace M
Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
[TBL] [Abstract][Full Text] [Related]
31. [Watchful waiting in incidental adenocarcinoma of the prostate].
Morán Pascual E; Dicapua Sacoto C; Trassierra Villa M; Pontones Moreno JL; Ruiz Cerdá JL; Jiménez Cruz JF
Actas Urol Esp; 2010 Nov; 34(10):854-9. PubMed ID: 21159280
[TBL] [Abstract][Full Text] [Related]
32. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
[TBL] [Abstract][Full Text] [Related]
33. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
Markun S
Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
[No Abstract] [Full Text] [Related]
34. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other.
Klotz L; Polascik TJ
Oncology (Williston Park); 2014 Nov; 28(11):950-C3. PubMed ID: 25741545
[No Abstract] [Full Text] [Related]
35. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
36. Seeking the Truth: Understanding the Impact of Missing Data on the Validity of the New Surveillance, Epidemiology and End Results Prostate with Watchful Waiting Database.
Laviana AA; Luckenbaugh AN; Wallis CJD
Eur Urol; 2020 Sep; 78(3):345-346. PubMed ID: 32059823
[No Abstract] [Full Text] [Related]
37. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
[TBL] [Abstract][Full Text] [Related]
38. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? No, focal therapy provides a false sense of security and no proven benefits.
Nelson JB
Oncology (Williston Park); 2014 Nov; 28(11):951-C3. PubMed ID: 25741546
[No Abstract] [Full Text] [Related]
39. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
40. The Prostate cancer Research International: Active Surveillance study.
Bangma CH; Bul M; Roobol M
Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
